New medicines to be prioritised in Europe over Britain, warn leading pharmaceutical companies

In a new snapshot survey of leading pharmaceutical businesses in the UK, companies have said that changes to the way NICE and NHS England (NHSE) assess new medicines, coming in to effect this month, will decrease access to the latest treatments, with new medicines for cancer set to be impacted the most. ​​The survey of member companies of the Association of the British Pharmaceutical Industry (ABPI), who deliver 80% of the most innovative medicines used by the NHS, asked questions relating to introduction of a £20m Budget Impact Test and changes to the Highly Specialised Treatments (HST) programme.​​​​​​ When asked